These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14722442)

  • 1. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals.
    Patel SM; Johnson S; Belknap SM; Chan J; Sha BE; Bennett C
    J Acquir Immune Defic Syndr; 2004 Feb; 35(2):120-5. PubMed ID: 14722442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nevirapine toxicity.
    Taiwo BO
    Int J STD AIDS; 2006 Jun; 17(6):364-9; quiz 370. PubMed ID: 16734954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
    McKoy JM; Bennett CL; Scheetz MH; Differding V; Chandler KL; Scarsi KK; Yarnold PR; Sutton S; Palella F; Johnson S; Obadina E; Raisch DW; Parada JP
    Drug Saf; 2009; 32(2):147-58. PubMed ID: 19236121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
    Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
    Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
    Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Jan; 49(51-52):1153-6. PubMed ID: 11198946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
    AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
    PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV drug nevirapine (Viramune): risk of severe hepatotoxicity.
    Wooltorton E
    CMAJ; 2004 Mar; 170(7):1091. PubMed ID: 15051689
    [No Abstract]   [Full Text] [Related]  

  • 10. [U.S. warns on some use of anti-AIDS drug].
    Hayashi T
    Yakugaku Zasshi; 2001 Sep; 121(9):679-82. PubMed ID: 11558152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
    Li ZC; Li HJ; Dai LL; Gao YQ; Cai WP; Li HY; Huang XJ; Zhang T; Wu H
    Chin Med J (Engl); 2010 Dec; 123(24):3587-90. PubMed ID: 22166636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk for immune-mediated liver reactions by nevirapine revisited.
    Medrano J; Barreiro P; Tuma P; Vispo E; Labarga P; Blanco F; Soriano V
    AIDS Rev; 2008; 10(2):110-5. PubMed ID: 18615121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital].
    Kondo W; Astori Ade A; Gomes Sel-K; Fernandes Rde B; Sasaki Md; Sbalqueiro RL
    Rev Bras Ginecol Obstet; 2008 Jan; 30(1):19-24. PubMed ID: 19142538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.
    Shahar E; Krivoy N; Weltfriend S; Pollack S
    Jpn J Infect Dis; 2004 Oct; 57(5):212-3. PubMed ID: 15507779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
    Saka B; Akakpo AS; Bassowa A; Dapam AN; Mahamadou G; Teclessou JN; Mouhari-Toure A; Laouali AY; Mensah E; Kombaté K; Pitché P
    Ann Dermatol Venereol; 2018 Dec; 145(12):773-776. PubMed ID: 30301570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
    Manfredi R; Calza L; Chiodo F
    J Acquir Immune Defic Syndr; 2004 Apr; 35(5):492-502. PubMed ID: 15021314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
    Hitti J; Frenkel LM; Stek AM; Nachman SA; Baker D; Gonzalez-Garcia A; Provisor A; Thorpe EM; Paul ME; Foca M; Gandia J; Huang S; Wei LJ; Stevens LM; Watts DH; McNamara J;
    J Acquir Immune Defic Syndr; 2004 Jul; 36(3):772-6. PubMed ID: 15213559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
    Sanne I; Mommeja-Marin H; Hinkle J; Bartlett JA; Lederman MM; Maartens G; Wakeford C; Shaw A; Quinn J; Gish RG; Rousseau F
    J Infect Dis; 2005 Mar; 191(6):825-9. PubMed ID: 15717255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
    Notter J; Bregenzer A; Vernazza P; Kahlert CR
    Swiss Med Wkly; 2019 Apr; 149():w20053. PubMed ID: 31017649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    Ena J; Amador C; Benito C; Fenoll V; Pasquau F
    Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.